

Open camera or QR reader and
scan code to access this article
and other resources online.



Epitope Mapping of an Anti-Mouse CCR8 Monoclonal Antibody C₈Mab-2 Using Flow Cytometry

Hiyori Kobayashi, Hiroyuki Suzuki, Tomohiro Tanaka, Mika K. Kaneko, and Yukinari Kato

The C-C motif chemokine receptor 8 (CCR8) is highly and selectively expressed in regulatory T (Treg) cells and is associated with tumor progression. The massive accumulation of Treg cells into tumors suppresses the effector function of CD8⁺ cells against tumor cells. Therefore, selective depletion of Treg cells using anti-CCR8 monoclonal antibodies (mAbs) reinvigorates antitumor immune responses and improves responses to cancer immunotherapy. Previously, we developed an anti-mouse CCR8 (mCCR8) mAb, C₈Mab-2, using the Cell-Based Immunization and Screening method. In this study, the binding epitope of C₈Mab-2 was investigated using flow cytometry. The mCCR8 extracellular domain-substituted mutant analysis showed that C₈Mab-2 recognizes the N-terminal region (1–33 amino acids) of mCCR8. Next, 1×alanine (or glycine) scanning and 2×alanine (or glycine) scanning were conducted in the N-terminal region. The results revealed that the ₁₇-DFFTAP₂₂ sequence is important for the recognition by C₈Mab-2, and Thr20 is a central amino acid of the epitope. These results revealed the involvement of the N-terminus of mCCR8 in the recognition by C₈Mab-2.

Keywords: mouse CCR8, monoclonal antibody, epitope mapping, alanine scanning, flow cytometry

Introduction

The C-C motif chemokine receptor 8 (CCR8) is a member of G protein-coupled receptors (GPCRs) family. The C-C motif chemokine ligands (CCLs), including CCL1, CCL8, CCL16, and CCL18, are known as ligands for human CCR8. CCL1 is the only ligand for CCR8,¹ which is produced by CD11b⁺CD14⁺ myeloid cells during the infiltration of regulatory T (Treg) cells into tumor.² Upon binding of CCL1 to CCR8, the FOXP3 is upregulated by the STAT3 pathway, and the activated CCR8⁺ Treg cells potently suppress antitumor immunity through secretion of granzyme B and IL-10.³ Increased expression of CCR8 is observed in Treg cells, especially in cancer patients.⁴ Patients with high levels of Treg cells exhibit poor prognoses and clinical outcomes in several cancers.⁵ Therefore, it has been proposed that depletion of tumor-infiltrated Treg cells could restore antitumor immunity and improve responses to tumor immunotherapy.⁶ Recent preclinical mouse models have revealed that depletion of Treg cells using an anti-mouse CCR8 (mCCR8) monoclonal antibody (mAb) exhibited strong antitumor responses through dramatic

changes of the intratumor CD8⁺ T-cell profile⁷ or enhanced the antitumor effects of antiprogrammed cell death 1 (PD-1) therapy.⁸

The understanding of the structural-based CCR activation is important for the development of therapeutic agents. Among the CCR family members, CCR2 and CCR5 have been structurally solved in both inactive and active states,^{9–12} while inactive state of CCR7 and CCR9 and active state of CCR1 and CCR6 structures are also characterized.^{13–16} Furthermore, the structures of CCR8 in complex with either the antagonistic mAb or the endogenous ligand CCL1 were determined, which provides the specific activation mechanism by CCL1 and inhibition by mAb.¹⁷

We have developed anti-mouse GPCR mAbs against CCR1 (clone C₁Mab-6),¹⁸ CCR3 (clones C₃Mab-2, C₃Mab-3, and C₃Mab-4),^{19–21} CCR8 (clones C₈Mab-1, C₈Mab-2, and C₈Mab-3),^{22–24} CXCR1 (clone Cx₁Mab-1),²⁵ CXCR3 (clone Cx₃Mab-4),²⁶ and CXCR4 (clone Cx₄Mab-1)²⁷ using the Cell-Based Immunization and Screening (CBIS) method. For the determination of the epitopes, we have faced difficulty using conventional methods such as enzyme-linked immunosorbent assay. In this study, epitope mapping of an anti-mCCR8 mAb was conducted by flow cytometry-based approaches.

Materials and Methods

Cell lines

Chinese hamster ovary (CHO)-K1 cell was obtained from the America Type Culture Collection (ATCC, Manassas, VA). Stable transfectants of CHO/mCCR8 were established in our previous study.²⁴ Briefly, synthesized DNA (Eurofins Genomics KK, Tokyo, Japan) encoding mCCR8 (Accession No.: NM_007720.2) was subcloned into a pCAG-Ble vector (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan). mCCR8 plasmid was transfected using a Neon Transfection System (Thermo Fisher Scientific Inc., Waltham, MA). CHO/mCCR8 cells were sorted using a cell sorter (SH800; Sony Corp., Tokyo, Japan) and cultivated in a medium containing 0.5 mg/mL of Zeocin (InvivoGen, San Diego, CA).

The chimeric and the point mutant plasmids were transfected into CHO-K1 cells using the Neon Transfection

System (Thermo Fisher Scientific Inc.). Stable transfectants were selected using SH800. Cells were cultured in Roswell Park Memorial Institute-1640 medium (Nacalai Tesque, Inc., Kyoto, Japan) supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher Scientific Inc.), 100 units/mL of penicillin, 100 μ g/mL streptomycin, and 0.25 μ g/mL amphotericin B (Nacalai Tesque, Inc.) at 37°C in a humidified atmosphere containing 5% CO₂. The stable transfectants were cultivated in a medium containing 0.5 mg/mL of Zeocin.

Plasmid construction

Synthesized DNAs (Eurofins Genomics KK) encoding mouse CCR3 (mCCR3; Accession No.: NM_009914.4) and mCCR8 were subcloned into a pCAG-Ble vector. Chimeric mutants including mCCR3 (mCCR8p1–33), mCCR3




FIG. 1. Schematic illustration of chimeric proteins. The four extracellular regions of mCCR8, including the N-terminal region (1–33 aa), ECL1 (92–105 aa), ECL2 (170–200 aa), and ECL3 (262–278 aa), were substituted into the corresponding regions of mCCR3. aa, amino acids; mCCR, mouse C-C motif chemokine receptor; ECL, extracellular loop.

(mCCR8p92–105), mCCR3 (mCCR8p170–200), and mCCR3 (mCCR8p262–278) were produced with a PA16 tag at their N-terminus using the HotStar HiFidelity polymerase kit (Qiagen Inc., Hilden, Germany). Alanine (or glycine) substitutions in the mCCR8 N-terminal region were conducted using QuikChange Lightning Site-Directed Mutagenesis Kits (Agilent Technologies Inc., Santa Clara, CA, USA). PCR fragments bearing the desired mutations were inserted into the pCAG-Ble vector (FUJIFILM Wako Pure Chemical Corporation) using the In-Fusion HD Cloning Kit (Takara Bio, Inc., Shiga, Japan).

Antibodies

C₈Mab-2 was established by the CBIS method.²³ NZ-1 (an anti-PA16 tag mAb) was described previously.²⁸ A secondary Alexa Fluor 488-conjugated anti-rat immunoglobulin G (IgG) was purchased from Cell Signaling Technology, Inc. (Danvers, MA).

Flow cytometry

Cells were harvested after brief exposure to 0.25% trypsin/1 mM ethylenediaminetetraacetic acid (Nacalai Tesque, Inc.). After washing with 0.1% bovine serum albumin in phosphate-buffered saline, cells were treated with C₈Mab-2 (10 μg/mL) or NZ-1 (1 μg/mL) for 30 minutes at 4°C and subsequently with Alexa Fluor 488-conjugated anti-rat IgG (1:2000; Cell Signaling Technology, Inc.). Fluorescence data were obtained using the SA3800 Cell Analyzer (Sony Corp.).

Results

Determination of the epitope of an anti-mCCR8 mAb by flow cytometry using chimeric proteins

We employed the CBIS method to develop an anti-mCCR8 mAb (clone C₈Mab-2).²³ C₈Mab-2 is applicable for

flow cytometry and immunocytochemistry. To investigate the binding epitope of C₈Mab-2, we focused on four extracellular regions of mCCR8, including the N-terminal region [1–33 amino acids (aa)], extracellular loop 1 (ECL1; 92–105 aa), ECL2 (170–200 aa), and ECL3 (262–278 aa). The four extracellular regions of mCCR8 were substituted into the corresponding regions of mCCR3, which possesses a similar structure to mCCR8. As shown in Figure 1, mCCR3 (mCCR8p1–33), mCCR3 (mCCR8p92–105), mCCR3 (mCCR8p170–200), and mCCR3 (mCCR8p262–278) were generated. The chimeric proteins were transiently expressed on CHO-K1 cells, and the reactivities to C₈Mab-2 were analyzed using flow cytometry (Fig. 2A). C₈Mab-2 reacted with mCCR3 (mCCR8p1–33) and CHO/mCCR8 cells, but not with other chimeric proteins (Fig. 2A). The cell surface expression of each mutant was confirmed by an anti-PA16 tag mAb, NZ-1 (Fig. 2B). These results indicated that the N-terminal region of mCCR8 is recognized by C₈Mab-2.

Determination of the C₈Mab-2 epitope by flow cytometry using 1×alanine scanning

Next, 1×alanine scanning was conducted in the N-terminal region except for Cys23. Thirty-two 1×alanine (or glycine) substitution mutants of mCCR8 were constructed, and the mutant proteins were stably expressed on CHO-K1 cells. The reactivity against C₈Mab-2 was assessed using flow cytometry. As shown in Figure 3A, C₈Mab-2 did not react with a mutant (T20A). In contrast, C₈Mab-2 reacted with the other 31 mutants. The cell surface expression of each mutant was confirmed by NZ-1 (Fig. 3B). These results showed that Thr20 of mCCR8 is important for C₈Mab-2 binding.




FIG. 2. Determination of the epitope of an anti-mCCR8 mAb by flow cytometry using chimeric proteins. C₈Mab-2 (10 μg/mL) (A) and an anti-PA16 tag mAb, NZ-1 (1 μg/mL) (B) were treated with CHO-K1 cells which were transiently expressed the chimeric proteins, CHO/mCCR8 or CHO-K1 cells for 30 minutes at 4°C, followed by the addition of Alexa Fluor 488-conjugated anti-rat IgG. Red lines show the cells with C₈Mab-2 or NZ-1 treatment, and black lines show cells treated with a blocking buffer as a negative control. CHO-K1 cell, Chinese hamster ovary-K1 cell; mCCR, mouse C-C motif chemokine receptor; IgG, Immunoglobulin G.




FIG. 3. Determination of the C₈Mab-2 epitope by flow cytometry using 1×alanine scanning. C₈Mab-2 (10 μg/mL) (A) and NZ-1 (1 μg/mL) (B) were treated with CHO-K1 cells which were stably expressed mutant proteins or CHO-K1 cells for 30 minutes at 4°C, followed by the addition of Alexa Fluor 488-conjugated anti-rat IgG. Red lines show the cells with C₈Mab-2 or NZ-1 treatment, and black lines show cells treated with a blocking buffer as a negative control. CHO-K1 cell, Chinese hamster ovary-K1 cell; IgG, Immunoglobulin G.

Determination of the C₈Mab-2 epitope by flow cytometry using 2×alanine scanning

We also examined the reactivity of C₈Mab-2 against 2×alanine (or glycine)-substituted mCCR8. We constructed thirty 2×alanine (or glycine)-substituted mutants in the N-terminal region of mCCR8 except for Cys23. The mutant proteins were transiently expressed on CHO-K1 cells. The reactivity against C₈Mab-2 was assessed using flow cytometry. As shown in Figure 4A, C₈Mab-2 did not react with the four mutants (D17A-F18A, F19A-T20A, T20A-A21G, and A21G-P22A). In contrast, C₈Mab-2 reacted with the other 26 mutants. The cell surface expression of each mutant was confirmed by NZ-1 (Fig. 4B). These results showed that a motif from Asp17 to Pro22 in mCCR8 is important for C₈Mab-2 recognition.

Discussion

In this study, we performed the flow cytometry-based epitope mapping of an anti-mouse CCR8 mAb (C₈Mab-2) using the chimeric proteins (Figs. 1 and 2). Furthermore, we determined that the ₁₇DFFTAP₋₂₂ is important for the recognition by C₈Mab-2 in the 2×alanine scanning (Fig. 4), and Thr20 is a central amino acid of the epitope by the 1×alanine scanning (Fig. 3). Figure 5 summarizes the epitope of C₈Mab-2. In the epitope mapping of an anti-human CCR8 mAb (clone mAb1), CCR8 chimeras, in which the N-terminus, ECL1, ECL2, or ECL3 were replaced with the corresponding sequences from human CCR5, were used.¹⁷ The mAb1 did not recognize ECL1-replaced CCR8 and ECL2-replaced CCR8, suggesting that both ECL1 and ECL2 are required for mAb1 binding.¹⁷ Because we could not determine the binding epitope of our other anti-mCCR8 mAbs




FIG. 4. Determination of the C₈Mab-2 epitope by flow cytometry using 2×alanine scanning. C₈Mab-2 (10 µg/mL) (A) and NZ-1 (1 µg/mL) (B) were treated with CHO-K1 cells which were transiently expressed mutant proteins or CHO-K1 cells for 30 minutes at 4°C, followed by the addition of Alexa Fluor 488-conjugated anti-rat IgG. Red lines show the cells with C₈Mab-2 or NZ-1 treatment, and black lines show cells treated with a blocking buffer as a negative control. CHO-K1 cell, Chinese hamster ovary-K1 cell; IgG, Immunoglobulin G.

(C₈Mab-1 and C₈Mab-3) in this study (data not shown), the substitution of two ECLs may be required for the identification of the epitopes of those anti-mCCR8 mAbs.

The “hot” tumor is characterized by the massive infiltration and enrichment with CD8⁺ effector T cells, which is important for the antitumor immune responses. Immune checkpoint

inhibitors such as anti-PD-1 mAbs are effective in hot tumors. However, the response rate of immune checkpoint inhibitors is still low due to the lack of CD8⁺ effector T-cell infiltration or accumulation of Treg cells suppressing the effector activities, which is characterized as “cold tumors.”^{29,30} Since CCR8 expression is increased in tumor-infiltrated Treg cells,




FIG. 5. Schematic illustration of the C₈Mab-2 epitope, which was identified by 1×alanine scanning and 2×alanine scanning. 17-DFFTAP₂₂ is important for the recognition by C₈Mab-2 in the 2×alanine scanning (underlined). Thr20 (red) is determined to be a central amino acid of the epitope by the 1×alanine scanning.

CCR8 is one of the promising target for depleting of Treg cells selectively in tumors.⁴ Anti-mCCR8 mAbs have been used to suppress cancer growth in several cancer models.^{7,8,31} Furthermore, an anti-human CCR8 mAb (S-531011) was developed.³² S-531011 has antibody-dependent cellular cytotoxicity activity against tumor-infiltrating CCR8⁺ Treg cells and neutralization activity against the CCR8 signaling.³² Meanwhile, there is no information about the relationship between the Treg cells-depleting activity and epitope of the mAbs. Our strategy for epitope identification would contribute not only to the understanding of mAb-epitope interaction but also to the improvement of those therapeutic mAbs.

Author's Contribution

H.K. and T.T. performed the experiments. M.K.K. and Y.K. designed the experiments. H.S. and M.K.K. analyzed the data. H.S. and Y.K. wrote the article. All authors have read and agreed to the published version of the article.

Author Disclosure Statement

The authors have no conflict of interest.

Funding Information

This research was supported in part by Japan Agency for Medical Research and Development (AMED) under Grant Numbers: JP23ama121008 (to Y.K.), JP23am0401013 (to Y.K.), JP23bm1123027 (to Y.K.), and JP23ck0106730 (to Y.K.), and by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI) grant nos. 21K20789 (to T.T.), 22K06995 (to H.S.), 21K07168 (to M.K.K.), and 22K07224 (to Y.K.).

References

- Roos RS, Loetscher M, Legler DF, et al. Identification of CCR8, the receptor for the human CC chemokine I-309. *J Biol Chem* 1997;272(28):17251–17254; doi: 10.1074/jbc.272.28.17251
- Plitas G, Konopacki C, Wu K, et al. Regulatory T cells exhibit distinct features in human breast cancer. *Immunity* 2016;45(5):1122–1134; doi: 10.1016/j.immuni.2016.10.032
- Barsheshet Y, Wildbaum G, Levy E, et al. CCR8(+)FOXP3(+) T(reg) cells as master drivers of immune regulation. *Proc Natl Acad Sci U S A* 2017;114(23):6086–6091; doi: 10.1073/pnas.1621280114
- Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? *Cancer Sci* 2019;110(7):2080–2089; doi: 10.1111/cas.14069
- Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression—implications for anticancer therapy. *Nat Rev Clin Oncol* 2019;16(6):356–371; doi: 10.1038/s41571-019-0175-7
- Kraehenbuehl L, Weng CH, Eghbali S, et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. *Nat Rev Clin Oncol* 2022;19(1):37–50; doi: 10.1038/s41571-021-00552-7
- Ueyama A, Nogami W, Nashiki K, et al. Immunotherapy targeting CCR8+ regulatory T cells induces antitumor effects via dramatic changes to the intratumor CD8+ T cell profile. *J Immunol* 2023;211(4):673–682; doi: 10.4049/jimmunol.2300067
- Kidani Y, Nogami W, Yasumizu Y, et al. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. *Proc Natl Acad Sci U S A* 2022;119(7); doi: 10.1073/pnas.2114282119
- Shao Z, Tan Y, Shen Q, et al. Molecular insights into ligand recognition and activation of chemokine receptors CCR2 and CCR3. *Cell Discov* 2022;8(1):44; doi: 10.1038/s41421-022-00403-4
- Isaikina P, Tsai CJ, Dietz N, et al. Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist. *Sci Adv* 2021;7(25); doi: 10.1126/sciadv.abg8685

11. Zheng Y, Qin L, Zacarias NV, et al. Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. *Nature* 2016;540(7633):458–461; doi: 10.1038/nature20605
12. Tan Q, Zhu Y, Li J, et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. *Science* 2013;341(6152):1387–1390; doi: 10.1126/science.1241475
13. Shao Z, Shen Q, Yao B, et al. Identification and mechanism of G protein-biased ligands for chemokine receptor CCR1. *Nat Chem Biol* 2022;18(3):264–271; doi: 10.1038/s41589-021-00918-z
14. Wasilko DJ, Johnson ZL, Ammirati M, et al. Structural basis for chemokine receptor CCR6 activation by the endogenous protein ligand CCL20. *Nat Commun* 2020;11(1):3031; doi: 10.1038/s41467-020-16820-6
15. Jaeger K, Bruenle S, Weinert T, et al. Structural basis for allosteric ligand recognition in the human CC chemokine receptor 7. *Cell* 2019;178(5):1222–1230.e1210; doi: 10.1016/j.cell.2019.07.028
16. Oswald C, Rappas M, Kean J, et al. Intracellular allosteric antagonism of the CCR9 receptor. *Nature* 2016;540(7633):462–465; doi: 10.1038/nature20606
17. Sun D, Sun Y, Janezic E, et al. Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8. *Nat Commun* 2023;14(1):7940; doi: 10.1038/s41467-023-43601-8
18. Ouchida T, Isoda Y, Nakamura T, et al. Establishment of a novel anti-mouse CCR1 monoclonal antibody C(1)Mab-6. *Monoclon. Antib. Immunodiagn. Immunother.* 2024;43(2):67–74; doi: 10.1089/mab.2023.0032
19. Tateyama N, Asano T, Suzuki H, et al. Epitope Mapping of Anti-Mouse CCR3 monoclonal antibodies using flow cytometry. *Antibodies (Basel)*2022;11(4); doi: 10.3390/antib11040075
20. Saito M, Harigae Y, Li G, et al. C(3)Mab-2: An Anti-Mouse CCR3 monoclonal antibody for immunocytochemistry. *Monoclon Antib Immunodiagn Immunother* 2022; 41(1):45–49; doi: 10.1089/mab.2021.0050
21. Asano T, Suzuki H, Tanaka T, et al. C(3)Mab-3: A monoclonal antibody for mouse cc chemokine receptor 3 for flow cytometry. *Monoclon Antib Immunodiagn Immunother* 2022;41(2):74–79; doi: 10.1089/mab.2021.0062
22. Suzuki H, Saito M, Asano T, et al. C(8)Mab-3: An Anti-Mouse CCR8 monoclonal antibody for immunocytochemistry. *Monoclon Antib Immunodiagn Immunother* 2022; 41(2):110–114; doi: 10.1089/mab.2022.0002
23. Saito M, Tanaka T, Asano T, et al. C(8)Mab-2: An anti-mouse C-C Motif chemokine receptor 8 monoclonal antibody for immunocytochemistry. *Monoclon Antib Immunodiagn Immunother* 2022;41(2):115–119; doi: 10.1089/mab.2021.0045
24. Saito M, Suzuki H, Tanaka T, et al. Development of an Anti-Mouse CCR8 monoclonal antibody (C(8)Mab-1) for flow cytometry and immunocytochemistry. *Monoclon Antib Immunodiagn Immunother* 2022;41(6):333–338; doi: 10.1089/mab.2021.0069
25. Li G, Tanaka T, Suzuki H, et al. Cx1Mab-1: A Novel Anti-mouse CXCR1 Monoclonal Antibody for Flow Cytometry. *Monoclon. Antib. Immunodiagn. Immunother.* 2024;43(2):59–66; doi: 10.1089/mab.2023.003
26. Ouchida T, Isoda Y, Tanaka T, et al. Cx(3)Mab-4: A Novel Anti-Mouse CXCR3 monoclonal antibody for flow cytometry. *Monoclon Antib Immunodiagn Immunother* 2024; doi: 10.1089/mab.2023.0024
27. Ouchida T, Suzuki H, Tanaka T, et al. Cx(4)Mab-1: A novel anti-mouse CXCR4 monoclonal antibody for flow cytometry. *Monoclon Antib Immunodiagn Immunother* 2023; 43(1):10–16; doi: 10.1089/mab.2023.0023
28. Kato Y, Kaneko MK, Kuno A, et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. *Biochem Biophys Res Commun* 2006; 349(4):1301–1307; doi: 10.1016/j.bbrc.2006.08.171
29. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. *Nat Rev Drug Discov* 2019;18(3):197–218; doi: 10.1038/s41573-018-0007-y
30. Karin N. Chemokines in the landscape of cancer immunotherapy: How they and their receptors can be used to turn cold tumors into hot ones? *Cancers (Basel)* 2021;13(24); doi: 10.3390/cancers13246317
31. Villarreal DO, L’Huillier A, Armington S, et al. Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer. *Cancer Res* 2018;78(18):5340–5348; doi: 10.1158/0008-5472.Can-18-1119
32. Nagira Y, Nagira M, Nagai R, et al. S-531011, a novel anti-human CCR8 antibody, induces potent antitumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells. *Mol Cancer Ther* 2023;22(9):1063–1072; doi: 10.1158/1535-7163.Mct-22-0570

Address correspondence to:

Yukinari Kato
 Department of Antibody Drug Development
 Tohoku University Graduate School of Medicine
 2–1, Seiryomachi
 Aoba-ku
 Sendai, Miyagi 980-8575
 Japan

E-mail: yukinari.kato.e6@tohoku.ac.jp

Received: January 23, 2024
 Accepted: February 24, 2024